Patents by Inventor Marc Derive

Marc Derive has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SOLUBLE TREM-1 AS A MARKER OF SEVERITY OR COMPLICATIONS FOR A SUBJECT SUFFERING FROM A CORONAVIRUS INFECTION
    Publication number: 20230273208
    Abstract: The use of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) as a marker in a method for identifying a subject suffering from a disease caused by a coronavirus such as COVID-19 at risk of having or developing a severe form and/or a complication or at risk of death, in a method for assessing the severity of a disease caused by a coronavirus such as COVID-19, and in a method for monitoring a subject suffering from a disease caused by a coronavirus such as COVID-19.
    Type: Application
    Filed: June 7, 2021
    Publication date: August 31, 2023
    Applicants: INOTREM, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE NANCY, UNIVERSITE DE LORRAINE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM
    Inventors: Jean-Jacques GARAUD, Marc DERIVE, Margarita SALCEDO-MAGGUILLI, Lucie JOLLY, Sébastien GIBOT, David MOULIN, Mihai NETEA, Aline DE NOOIJER
  • TREM-1 INHIBITOR FOR USE IN THE TREATMENT OF A SUBJECT SUFFERING FROM A CORONAVIRUS INFECTION
    Publication number: 20230201301
    Abstract: An inhibitor of triggering receptor expressed on myeloid cells 1 (TREM-1) for use in the treatment of coronavirus disease 2019 (COVID-19) in a subject in need thereof, in particular in a subject suffering from a severe form and/or a complication of COVID-19. Also, the use of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) as a marker in a method for identifying a subject suffering from COVID-19 susceptible to respond to a TREM-1 inhibitor and in a method for monitoring the effectiveness of TREM-1 inhibitor administered to a subject suffering from COVID-19.
    Type: Application
    Filed: June 7, 2021
    Publication date: June 29, 2023
    Applicant: INOTREM
    Inventors: Marc DERIVE, Margarita SALCEDO-MAGGUILLI, Jean-Jacques GARAUD, Simon LAMBDEN, Aurélie OLIVIER
  • USE OF SOLUBLE TREM-1 LEVELS FOR IDENTIFYING SUBJECTS SUSCEPTIBLE TO RESPOND TO AN ANTI-INFLAMMATORY THERAPY
    Publication number: 20210364532
    Abstract: A method for identifying human subjects suffering from an inflammatory disorder susceptible to respond to a therapy, in particular to a TREM-1 inhibitor. In particular, an in vitro method for identifying a human subject suffering from an inflammatory disorder, preferably an acute inflammatory disorder such as SIRS, sepsis or septic shock, susceptible to respond to a therapy, in particular to a TREM-1 inhibitor. The method includes the steps of a) measuring the level of soluble triggering receptors expressed on myeloid cells-1 (sTREM-1) in a biological sample from the human subject, comparing the level of sTREM-1 measured at step a) to a predetermined sTREM-1 value, and c) identifying a human subject suffering from an inflammatory disorder with a level of sTREM-1 measured at step a) higher than the predetermined sTREM-1 value of step b) as susceptible to respond to a therapy, in particular to a TREM-1 inhibitor.
    Type: Application
    Filed: September 27, 2019
    Publication date: November 25, 2021
    Applicant: INOTREM
    Inventors: Marc DERIVE, Aurelie OLIVIER, Kevin CARRASCO, Martin KOCH, Margarita SALCEDO-MAGGUILLI, Amir BOUFENZER, Lucie JOLLY, Jean-Jacques GARAUD
  • Methods and kits for predicting the risk of having a cardiovascular disease or event
    Patent number: 10948498
    Abstract: A cardiovascular event or disease is prevented or treated in a subject by measuring the expression level of soluble Triggering Receptors Expressed on Myeloid cells-1 (sTREM-1) level in a sample from the subject and comparing it to a reference level. Based on this comparison, subjects that are at risk of having or developing a cardiovascular event or disease are identified, and administered a suitable therapy.
    Type: Grant
    Filed: August 8, 2014
    Date of Patent: March 16, 2021
    Assignees: INOTREM, APHP (Assistance Publique-Hôpitaux de Paris), INSERM (Institut National de la Santé et de la Recherche Médicale), Université de Lorraine
    Inventors: Marc Derive, Sebastien Gibot, Hafid Ait-Oufella, Amir Boufenzer, Tabasomme Simon, Nicolas Danchin
  • Inhibiting peptides derived from TREM-like transcript 1 (TLT-1) and uses thereof
    Patent number: 9815883
    Abstract: The present invention relates to polypeptides fragments derived from the protein TLT-1 and their uses for the treatment of inflammatory conditions and more particularly for the treatment of sepsis.
    Type: Grant
    Filed: April 29, 2015
    Date of Patent: November 14, 2017
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), UNIVERSITE DE LORRAINE
    Inventors: Sebastien Gibot, Marc Derive
  • Inhibiting peptides derived from triggering receptor expressed on myeloid cells-1 (TREM-1) TREM-like transcript 1 (TLT-1) for treatment of cardiovascular diseases
    Patent number: 9657081
    Abstract: The present invention relates to a peptide comprising at least 6 consecutive amino acid selected from the amino acid sequence SEQ ID NO: 2 and a function-conservative variant. The invention also relates to a peptide comprising at least 6 consecutive amino acid selected from the amino acid sequence SEQ ID NO: 1 or SEQ ID NO: 2 and a function-conservative variant for use in the treatment of a cardiovascular disease.
    Type: Grant
    Filed: September 9, 2013
    Date of Patent: May 23, 2017
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE LORRAINE
    Inventors: Sebastien Gibot, Amir Boufenzer, Hafid Ait-Oufella, Marc Derive
  • METHODS AND KITS FOR PREDICTING THE RISK OF HAVING A CARDIOVASCULAR DISEASE OR EVENT
    Publication number: 20160187352
    Abstract: The present invention relates to a method for diagnosing a cardiovascular event or disease in a subject by measuring sTREM-1 level in a sample.
    Type: Application
    Filed: August 8, 2014
    Publication date: June 30, 2016
    Inventors: Marc DERIVE, Sebastien GIBOT, Hafid AIT-OUFELLA, Amir BOUFENZER, Tabasomme SIMON, Nicolas DANCHIN
  • Inhibiting peptides derived from TREM-like transcript 1 (TLT-1) and uses thereof
    Patent number: 9255136
    Abstract: Polypeptide The present invention relates to polypeptides fragments derived from the protein TLT-1 have been isolated and are useful in pharmaceutical preparations used for the treatment of inflammatory conditions such as sepsis.
    Type: Grant
    Filed: April 8, 2011
    Date of Patent: February 9, 2016
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite de Lorraine
    Inventors: Sebastien Gibot, Marc Derive
  • INHIBITING PEPTIDES DERIVED FROM TREM-LIKE TRANSCRIPT 1 (TLT-1) AND USES THEREOF
    Publication number: 20160015773
    Abstract: The present invention relates to polypeptides fragments derived from the protein TLT-1 and their uses for the treatment of inflammatory conditions and more particularly for the treatment of sepsis.
    Type: Application
    Filed: April 29, 2015
    Publication date: January 21, 2016
    Applicants: Institut National de la Sante et de la Recherche Medicale (INSERM), UNIVERSITE DE LORRAINE
    Inventors: Sebastien GIBOT, Marc DERIVE
  • INHIBITING PEPTIDES DERIVED FROM TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS-1 (TREM-1) TREM-LIKE TRANSCRIPT 1 (TLT-1) AND USES THEREOF
    Publication number: 20150232531
    Abstract: The present invention relates to a peptide comprising at least 6 consecutive amino acid selected from the amino acid sequence SEQ ID NO: 2 and a function-conservative variant. The invention also relates to a peptide comprising at least 6 consecutive amino acid selected from the amino acid sequence SEQ ID NO: 1 or SEQ ID NO: 2 and a function-conservative variant for use in the treatment of a cardiovascular disease.
    Type: Application
    Filed: September 9, 2013
    Publication date: August 20, 2015
    Inventors: Sebastien Gibot, Amir Boufenzer, Hafid Ait-Oufella, Marc Derive
  • INHIBITING PEPTIDES DERIVED FROM TREM-LIKE TRANSCRIPT 1 (TLT-1) AND USES THEREOF
    Publication number: 20130029921
    Abstract: The present invention relates to polypeptides fragments derived from the protein TLT-1 and their uses for the treatment of inflammatory conditions and more particularly for the treatment of sepsis.
    Type: Application
    Filed: April 8, 2011
    Publication date: January 31, 2013
    Inventors: Sebastien Gibot, Marc Derive